Acute vasospasm of the transclivally exposed basilar artery of anesthetised cats was produced by the subarachnoid injection of platelet-rich plasma (PRP) treated with enough adenosine diphosphate (ADP) to induce platelet aggregation and secretion. Vasorelaxation was produced by the topical application of the calcium antagonist verapamil. Changes in the internal diameter of the basilar artery were determined by measuring the blood column diameter from photomicrographs taken sequentially, at 5 minute intervals, through the operating microscope. Changes in blood vessel diameter are expressed as a plus or minus percentage of the pretreatment diameter. Arterial blood pressure and blood gas values were kept in the physiological range for the cat.
Cerebral vasospasm is a major cause of mortality and morbidity in patients with aneurysmal subarachnoid hemorrhage (SAH) who survive to reach hospital. Platelet produced spasmogens, such as serotonin, prostaglandins and thromboxanes, have been implicated as a cause of experimental and clinical cerebral vasospasm (Yamamoto et al., 1972; Latorre et al., 1974; Peterson etal.,1975; Boullinetal.,1976; Hagenetal.,1977; Zervasetal., 1979) . These substances may produce vasospasm by altering the permeability of the vascular smooth muscle cell to extracellular calcium or to calcium stored in the sarcoplasmic reticulum, permitting its entry into the cell where it becomes available for actin-myosin coupling (Peterson and Leblanc, 1976) . With a constant supply of spasmogens the constriction would persist and vasospasm would ensue.
Much enthusiasm has recently been generated for the use of calcium channel blockers in the treatment of angina pectoris secondary to coronary vasospasm (Antman et al., 1976; Johnson etal., 1981 ; Pepine and Conti, 1981) . Preliminary reports attest to the usefulness of these agents in the treatment of experimental and clinical cerebral vasospasm and stroke (Peterson et al., 1969; Allen and Bahr, 1979; Allen etal., 1983; Auer etal., 1981; Brandt et al., 1979; Edvinsson et al., 1979; Takagi et al., 1979; Brandt, 1980; Cohen and Allen, 1980; Nagai etal., 1980; Brandt etal., 1981; Gaab etal., 1982; White et al., 1982; Allen et al., LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES 1983) . This study documents the reversal of acute vasospasm, produced by platelet-rich plasma (PRP) activated to aggregate and release platelet contents by treatment with ADP, by the topical application of the calcium channel blocker verapamil.
MATERIALS AND METHODS
Eleven male and female mongrel cats were anesthetised with intraperitoneal pentobarbital, 30-35 mg per kg, and were given atropine, 0.04 mg per kg intramuscularly. A tracheostomy was performed and the tracheostomy tube was connected to a Harvard Small Animal Ventilator which was adjusted to assure constant arterial blood gas values. Catheterization of the femoral artery and vein permitted continuous monitoring of arterial blood pressure and blood gases and the intravenous administration of pentobarbital as required to maintain anesthesia. Prior to any intravenous infusion, 4.5 cc of venous blood was withdrawn for the production of platelet-rich plasma.
The transclival exposure of the basilar artery was performed by a method previously described (Kapp et al., 1968; Echlin, 1971; Peterson et al., 1975) . The dura was elevated using the operating microscope. The arachnoid membrane was left intact and kept moist by intermittent application of Elliot's A solution (mean pH 6.507). Arterial constriction was produced by injecting 0.4 cc of PRP and ADP, prepared as described below, with a number 27 needle and a tuberculin syringe. Vasodilatation was produced by covering the arachnoid membrane with 0.4 cc of verapamil (mean pH 6.609; 0.1 mg per kg) for 5 minutes.
Initial photographs were taken 30 to 60 minutes after the elevation of the dura and immediately before treatment with PRP-ADP. Photographs were again taken at 5 minute intervals after the subarachnoid injection of PRP-ADP or its controls, for a period of 30 minutes. At that time, verapamil was applied to the arachnoid membrane and its effects documented in a similar manner for a period of up to 60 minutes, at which time the experiment was repeated. The operative field was dried using a microsuction device before each photographic exposure and was covered with Elliot's A solution after each photograph had been taken. The photographic slides were projected at constant magnification with a 35 mm slide projector. The blood column diameter within the basilar artery was measured at 3 or 4 points along its length using a millimeter ruler. This method of quantifying changes in the inner diameter of cerebral blood vessels is widely used and has been found to be accurate and reproducible. (Kappetal., l968; Echlin, 1971; Petersonetal., 1973a; Peterson et al., 1975) . The changes in the blood column diameter produced by treatment with PRP-ADP and verapamil are expressed as negative (vasoconstriction) or positive (vasodilation) percentage changes of the initial control diameter which is taken to be the blood column diameter at 30 to 60 minutes after the elevation of the dura, prior to any treatment, and is expressed as 0%. Statistical analysis was performed using the student t test for the comparison of 2 means. PRP was prepared by mixing 0.5 cc of a 3.8% solution of sodium citrate with 4.5 cc of whole autogenous venous blood in a glass tube. The mixture was allowed to sediment by force of gravity for 2 hours (Marcinkiewicz et al., 1978) . The PRP was verified on one occasion to contain 300,000 platelets per microliter. Just prior to the subarachnoid injection the platelets were stimulated to aggregate by mixing 0.4 cc of the PRP with 25 micromolar of ADP in a Born aggregometer for one minute. Visible aggregates were seen in all cases.
Platelet-free plasma (PFP) was prepared after the method of Milton and co-workers (1978) by mixing 2.25 cc of whole venous blood with 0.25 cc of 3.8% sodium citrate in a plastic tube and centrifuging at 1000 RPM (HOG) for 15 minutes at room temperature. The supernatant was centrifuged at 4300 rpm for 15 minutes at room temperature. The new supernatant was centrifuged at 30,000 rpm for 15 minutes at 4°C. The final supernatant was incubated at 37°C until ready for injection into the SAS, approximately 30 minutes after its preparation. The absence of platelets was verified in all cases. Twenty-five micromolar of ADP acted as a control for the ADP used for platelet aggregation. 0.04 cc of Elliott's A solution served as a control for the volume of the platelet aggregate injected into the SAS.
RESULTS
Platelet-free plasma and ADP, Elliot's A solution or ADP alone had no significant vasoconstrictive effects on the basilar artery. Platelet-rich plasma and ADP produced prompt vasoconstriction of the basilar artery that attained a maximum at 5 minutesafterinjection(meanconstriction:-40.73% ± 2.84SEM) and persisted for the 30 minute observation period (mean constriction: -23.04% ± 3.51 SEM). At that time, the topical application of verapamil produced rapid and dramatic vasorelaxation of the blood vessels (mean dilatation at 5 minutes: + 52.74% ± 18.14SEM)whichpersistedinadecrementalfashion for the 60 minute observation period, at which time the mean dilation was 6.78% ± 7.52 SEM (Table I, Figure 1 and Figure  2 ). The reinjection of PRP-ADP, however, again produced vasoconstriction of a severity similar to that produced by the first injection. Verapamil did not, therefore, prevent vasoconstriction following a second injection of PRP-ADP. Reapplication of verapamil did produce prompt and dramatic reversal of the vasoconstriction produced by the second injection of PRP-ADP, in a manner similar to the first application of verapamil (Table 2, Figure 3 ). The vasodilation produced by verapamil is not ascribed to its pH (mean pH: 6.609) because application of Elliot's A solution (mean pH: 6.507) had no such effect.
Slight pial or subarachnoid bleeding was incurred in some animals with the injection of the PRP-ADP. In 2 animals this was felt to be of a significant magnitude and these cases are analysed separately. In these 2 cases subarachnoid hemorrhage was produced by the nicking of a side branch and produced spasm, of a similar magnitude and time course as that produced by PRP-ADP, which was readily reversed with verapamil (Table  3) . A statistically insignificant increase in the mean arterial blood pressure (MABP) was noted at 5 and 30 minutes after the subarachnoid injection of PRP-ADP (Table 4 ). This was not seen with verapamil. There were no significant changes in the pC0 2 values during the course of the experiments (Table 5 ). 49(11.74)  -34.64(12.70)  -29.23(12.60)  -30.74(14.88)  -30.44(12.20 
PRP-ADP = Platelet-rich plasma and adenosine diphosphate SD = Standard Deviation

Figure 3 -Effects (mean and SEM) of the subarachnoid injection of PRP-ADP (closed arrow) and of verapamil (open arrow) on the basilar artery of the cat, when PRP-ADP is injected 60 minutes after a treatment with verapamil. Negative percentages indicate vasoconstriction and positive percentages indicate vasodilatation. Vasoconstriction is produced despite prior treatment with verapamil, but is readily reversed by the reapplication of verapamil.
DISCUSSION
Despite more than twenty years of laboratory experimentation and numerous trials of treatment of the clinical syndrome with a variety of drug regimens (Sundtetal., l973;Zervasetal., 1979;  Flamm, 1980) there is no universally effective pharmacological treatment of cerebral vasospasm. One of the major factors responsible for this is the difficulty of producing a reliable model for the production of delayed vasospasm that mimics the clinical condition. Most of the advances in our understanding of vasospasm, therefore, have come from experimentation on acute experimental models. The present study uses Echlin's model (Echlin, 1971) as modified by Kapp and his co-workers (Kapp et al., 1968) to insure reproducibility by stabilizing physiological conditions. We have further refined this model so as to avoid the mechanical trauma incurred with the resection of the arachnoid membrane and to eliminate the risk of drying of the blood vessels, shown by Kapp et al. to have a potent vasoconstrictive effect (Kapp et al., 1968) . This is accomplished by leaving the arachnoid membrane intact and injecting the spasmogen directly into the SAS with a fine needle. The presence Volume II. No. I -February 1984 of a relatively intact arachnoid membrane also prevents any ambient blood from coming into direct contact with the vessels under investigation. Besides eliminating these potential sources of artifactual vasoconstriction, the injection of the spasmogen into the SAS more closely reproduces the acute phase of SAH.
The subarachnoid injection of PRP-ADP and subarachnoid hemorrhage produced by nicking of a side branch of the basilar artery produced a statistically insignificant elevation of the mean arterial blood pressure (MABP). Espinosaand co-workers noted a 25% increase in MABP in 50 to 70% of their monkeys during the creation of chronic experimental SAH (Espinosa et al., 1982) . They found no relationship between this increase in MABP and the development of vasospasm at any time after SAH. In our experiments the increase in MABP may represent a reflex response to brainstem ischemia secondary to the constriction of the basilar artery. The choice of ADP-activated PRP to cause acute experimental vasospasm is pertinent in 3 ways: (I) Platelet aggregation has been noted to be increased in patients with spontaneous coronary artery vasospasm (Robertson et al., 1980) . By analogy abnormally increased platelet aggregation may be a factor in the genesis of cerebral vasospasm. (2) The platelet fraction of whole blood contains a number of vasoactive compounds which may be involved in the genesis of the acute phase of cerebral vasospasm. (3) Most of the putative spasmogens associated with platelets are produced by brain tissue (Wolfe, 1981) . Endogenous biosynthesis of PG-E 2 , PG-F 2 a, and PG-D 2 has been demonstrated in the cat cerebral cortex, hippocampus and cerebellum and synthesis of these compounds and of thromboxane B 2 has been demonstrated in the rat and guinea pig cerebral cortex (Wolfe, 1981) . Predominant amongst these, in the cerebral cortex of most of the species studied, is PG-F 2 a, which has been demonstrated to be a potent vasoconstrictor. Prostaglandins F-2a and E 2 are seen in increased amounts in the CSF of patients with subarachnoid hemorrhage, stroke, meningoencephalitis and following brain surgery, all conditions which are often associated with vasospasm (Wolfe and Mamer, 1974; Carasso et al., 1977; Hagen et al., 1977) .
The final common pathway leading to vasospasm must involve calcium-mediated actin and myosin coupling (Peterson and Leblanc, 1976) . Interference with this process by chelation with EDTA or by promotion of cyclic-AMP-mediated calcium ion sequestration has been demonstrated to reverse experimentally induced vasospasm (Peterson et al, 1969; Peterson et al, 1973a; Peterson et al., 1973b; Peterson et al., 1975) . Our experiments document that the topical application of a calcium antagonist results in consistent and dramatic reversal of acute experimental vasospasm. They also demonstrate that the effects of this drug are transient, and that vasospasm can be induced in the basilar artery 60 minutes after treatment with verapamil. This indicates that as long as blood vessels are exposed to spasmogens, a continuous supply of calcium blockers may be required to assure ongoing antagonism of their action. This may limit the usefulness of verapamil itself, given systemically, in view of its known hypotensive effects (Lewis, 1980) . Nonetheless, calcium channel blockers have marked spasmolytic properties and therefore show promise for the treatment of cerebral vasospasms (Allen etal., 1983) .
